The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990.

Human gene therapy ·Vol. 1 ·No. 3 ·1990-00-00 ·Pages 331-62

Anderson WF, Blaese RM, Culver K

Abstract

暂无摘要

Keywords

Biomedical and Behavioral Research Genetics and Reproduction Human Gene Therapy Subcommittee National Institutes of Health Points to Consider: Transfer of Recombinant DNA into Human Subjects

MeSH Terms

Child DNA, Recombinant Ethical Review Ethics Federal Government Genetic Therapy Government Government Regulation Human Experimentation Humans Immunologic Deficiency Syndromes Methods National Institutes of Health (U.S.) Patient Selection Reference Standards Research Design Research Subjects Social Control, Formal United States

Chemicals

DNA, Recombinant

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Anderson W French

Blaese R Michael

Culver Kenneth

Article Info

Journal

Human gene therapy

Abbr.

Hum Gene Ther

ISSN

1043-0342

DOI

10.1089/hum.1990.1.3-331

Published

1990-00-00

Pages

331-62

Language

English

Region

United States

NLM ID

9008950

External Links

PubMed source DOI: 10.1089/hum.1990.1.3-331 View journal details

Analysis Services

The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990.

Contact

WeChat Official Account